Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2017-08-10 Earnings Release
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
EVOTEC ANNOUNCES FIRST HALF YEAR 2017 RESULTS AND CORPORATE UPDATE
Earnings Release Classification · 100% confidence The document is explicitly titled "EVOTEC ANNOUNCES FIRST HALF YEAR 2017 RESULTS AND CORPORATE UPDATE" and contains detailed financial figures (revenues, EBITDA, R&D expenses) broken down by segment for the first half of 2017 (H1 2017). It also mentions that the company will hold a conference call to discuss these results. This content structure—a comprehensive financial review for a period shorter than a full year—is characteristic of an Interim/Quarterly Report. Although it is presented as a news release, the substance is the full report data, making 'Interim / Quarterly Report' (IR) the most appropriate classification over a simple 'Earnings Release' (ER) or 'Report Publication Announcement' (RPA), given its length and detail. The note at the end also refers to the 'half-year report'. H1 2017
2017-08-10 English
Präsentation H1 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Evotec AG, H1 2017 Interim Report' and contains detailed financial performance metrics, operational highlights, and strategic updates for the first six months of 2017. It provides substantive financial data (revenues, EBITDA, R&D expenses) and management analysis, fitting the definition of an Interim/Quarterly Report (IR). It is not a mere announcement (RPA) as it contains the actual report content. H1 2017
2017-08-10 English
EVOTEC AG TO REPORT FIRST HALF-YEAR 2017 RESULTS ON 10 AUGUST 2017
Report Publication Announcement Classification · 99% confidence The document is a news release dated August 3, 2017, announcing that EVOTEC AG will report its financial results for the first half of 2017 on August 10, 2017. It provides details for the subsequent conference call and webcast. This is not the actual financial report (which would be an IR or ER), but rather an announcement about the *release* of those results and the associated call. According to Rule 2, if a document announces the publication of a report and provides details for accessing the event where results are discussed, it fits the description of a Report Publication Announcement (RPA). It is not a full Earnings Release (ER) as it contains no actual results, only the schedule for the release.
2017-08-03 English
EVOTEC AND FRAUNHOFER IME-SP SIGN STRATEGIC COLLABORATION ON IPSC TECHNOLOGY
M&A Activity Classification · 99% confidence The document is a press release dated August 3, 2017, announcing a strategic collaboration between Evotec AG and Fraunhofer IME-SP regarding iPSC technology. It is explicitly labeled as 'DGAP-News' and discusses an alliance/partnership, not a mandatory periodic financial filing (like 10-K or IR) or a specific shareholder action (like AGM or DIV). Since it is a general corporate announcement about a business development (alliance), and it does not fit into the more specific categories like M&A (TAR), Capital Change (CAP), or Earnings Release (ER), it falls best under the general regulatory announcement category, which is RNS (Regulatory Filings), as it is disseminated via the DGAP service which handles 'Regulatory Announcements, Financial/Corporate News and Press Releases'. The document length (7281 chars) is substantial enough that it is the primary announcement itself, not just a notice of publication (RPA).
2017-08-03 English
Evotec AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly references Article 26a of the WpHG (German Securities Trading Act). It details a 'Conditional capital increase' and provides the 'New total number of voting rights' as of 31.07.2017. This type of announcement, focusing on changes to the total number of shares/voting rights, is a specific regulatory disclosure. It is not a full annual report (10-K), an earnings release (ER), or a general management/board change (MANG). While it relates to capital structure, the specific focus on the total voting rights count aligns best with a specialized regulatory filing or a capital-related disclosure. Given the options, 'Share Issue/Capital Change' (SHA) covers changes in capital structure, but the document is specifically a 'Total Voting Rights Announcement' which is often categorized under general regulatory disclosures if a more specific code isn't available. However, since it details a capital measure ('Conditional capital increase'), SHA is a strong candidate. Alternatively, since it is a formal regulatory disclosure transmitted via DGAP, RNS (Regulatory Filings) is the fallback. Given the specific nature of reporting voting rights following a capital measure, SHA is more precise than RNS, although RNS is also plausible for any non-standard regulatory notice. Since the core content is about the resulting share count after a capital measure, SHA is the most appropriate fit among the specific codes.
2017-07-31 English
Telefonkonferenz/Webcast zur Akquisition von Aptuit
Investor Presentation Classification · 98% confidence The document is titled 'Evotec to acquire Aptuit Expanding leadership in external innovation' and contains sections like 'Investor and Analyst call, 31 July 2017', 'Welcome from the management team', 'Agenda', 'Strategic rationale and transaction overview', and 'Financials'. The content is structured as a presentation detailing the rationale, capabilities, and financial impact of an acquisition (M&A activity). While it discusses financials, the primary purpose is to present the strategic transaction to investors and analysts, which strongly suggests an Investor Presentation (IP) or a presentation related to a major corporate action. Since the core theme is the acquisition of Aptuit, it falls under M&A Activity (TAR) or Investor Presentation (IP). Given the format (slides/presentation structure) and the focus on strategic rationale and transaction overview, Investor Presentation (IP) is the most fitting category for the material itself, although it is directly related to a takeover bid (TAR). However, the document is clearly a presentation deck used for communication, making IP the best fit for the document type.
2017-07-31 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.